TransEnterix Announces Klinikum Esslingen to Initiate a Senhance Surgical System Program
January 21 2020 - 6:55AM
Business Wire
TransEnterix, Inc. (NYSE American:TRXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to improve minimally invasive surgery, today announced
that the Klinikum Esslingen, a hospital in southern Germany close
to Stuttgart, has entered into an agreement to lease and utilize a
Senhance® System. The Senhance System has been installed at the
hospital facility and cases are expected to begin shortly. This
placement is one of the two placements referenced in the Company’s
January 6, 2020 press release.
Klinikum Esslingen is a major German hospital that serves as the
academic teaching hospital of the University of Tübingen. The
facility has more than 660 beds and performs more than 9,000
surgical interventions each year.
The Senhance® Surgical System is the first and only digital
laparoscopic platform designed to maintain laparoscopic MIS
standards while providing digital benefits such as haptic feedback,
robotic precision, comfortable ergonomics, advanced instrumentation
including, 3 mm microlaparoscopic instruments, eye-sensing camera
control and reusable standard instruments to help maintain
per-procedure costs similar to traditional laparoscopy.
“We are committed to support and grow the outstanding minimally
invasive surgical program of Klinikum Esslingen with the addition
of a Senhance System,” said Anthony Fernando, president and chief
executive officer at TransEnterix. “We continue to see strong
momentum in Germany, and the expansion into such a prestigious
hospital as the Klinikum Esslingen is a significant milestone in
the advancement of digital laparoscopy with Senhance in
Europe.”
“We have created a strong, multidisciplinary program in
minimally invasive surgery at our hospital,” said Professor Dr.
Ludger Staib, chief physician of the clinic for general and
visceral surgery at the Klinikum Esslingen. “We believe modern
technology can help offer our patients the most precise and least
invasive surgery possible, and we appreciate the ability to build
on our strong existing minimally invasive program with the Senhance
that will allow for maximum precision, visualization and control
during delicate surgeries.”
About TransEnterix
TransEnterix is a medical device company that is digitizing the
interface between the surgeon and the patient to improve minimally
invasive surgery by addressing the clinical and economic challenges
associated with current laparoscopic and robotic options in today's
value-based healthcare environment. The Company is focused on the
commercialization of the Senhance Surgical System, which digitizes
laparoscopic minimally invasive surgery. The system allows for
robotic precision, haptic feedback, surgeon camera control via eye
sensing and improved ergonomics while offering responsible
economics. The Senhance Surgical System is available for sale in
the US, the EU, Japan and select other countries. For more
information, visit www.transenterix.com.
Forward-Looking Statements
This press release includes statements relating to the Senhance
System and the Klinikum Esslingen hospital initiating a program
with the Senhance System. These statements and other statements
regarding our future plans and goals constitute "forward looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control and which
may cause results to differ materially from expectations and
include whether TransEnterix will continue to see strong momentum
in Germany, whether the expansion of the Senhance System into
Klinikum Esslingen will serve as a significant milestone in the
advancement of digital laparoscopy in Europe, and whether the use
of a Senhance System in the minimally invasive program at Klinikum
Esslingen will allow for maximum precision, visualization and
control during delicate surgeries. For a discussion of the risks
and uncertainties associated with TransEnterix's business, please
review our filings with the Securities and Exchange Commission
(SEC), including our Annual Report on Form 10-K for the year ended
December 31, 2018, filed with the SEC on February 27, 2019 and our
other filings we make with the SEC. You are cautioned not to place
undue reliance on these forward looking statements, which are based
on our expectations as of the date of this press release and speak
only as of the origination date of this press release. We undertake
no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200121005296/en/
For TransEnterix, Inc. Investor Contact: Mark Klausner, +1
443-213-0501 invest@transenterix.com or Media Contact: Terri
Clevenger, +1 203-682-8297 terri.clevenger@icrinc.com
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Apr 2023 to Apr 2024